Richard Van Krieken1, Joan C Krepinsky2. 1. Department of Medicine, Division of Nephrology, St. Joseph's Hospital, McMaster University, 50 Charlton Ave E, T3311, Hamilton, ON, L8N 4A6, Canada. 2. Department of Medicine, Division of Nephrology, St. Joseph's Hospital, McMaster University, 50 Charlton Ave E, T3311, Hamilton, ON, L8N 4A6, Canada. krepinj@mcmaster.ca.
Abstract
PURPOSE OF REVIEW: Diabetic nephropathy, a major microvascular complication of diabetes and the most common cause of end-stage renal disease, is characterized by prominent accumulation of extracellular matrix. The membrane microdomains caveolae, and their integral protein caveolin-1, play critical roles in the regulation of signal transduction. In this review we discuss current knowledge of the contribution of caveolin-1/caveolae to profibrotic signaling and the pathogenesis of diabetic kidney disease, and assess its potential as a therapeutic target. RECENT FINDINGS: Caveolin (cav)-1 is key to facilitating profibrotic signal transduction induced by several stimuli known to be pathogenic in diabetic nephropathy, including the most prominent factors hyperglycemia and angiotensin II. Phosphorylation of cav-1 on Y14 is an important regulator of these responses. In vivo studies support a pathogenic role for caveolae in the progression of diabetic nephropathy. Targeting caveolin-1/caveolae would enable inhibition of multiple profibrotic pathways, representing a novel and potentially potent therapeutic option for diabetic nephropathy.
PURPOSE OF REVIEW: Diabetic nephropathy, a major microvascular complication of diabetes and the most common cause of end-stage renal disease, is characterized by prominent accumulation of extracellular matrix. The membrane microdomains caveolae, and their integral protein caveolin-1, play critical roles in the regulation of signal transduction. In this review we discuss current knowledge of the contribution of caveolin-1/caveolae to profibrotic signaling and the pathogenesis of diabetic kidney disease, and assess its potential as a therapeutic target. RECENT FINDINGS:Caveolin (cav)-1 is key to facilitating profibrotic signal transduction induced by several stimuli known to be pathogenic in diabetic nephropathy, including the most prominent factors hyperglycemia and angiotensin II. Phosphorylation of cav-1 on Y14 is an important regulator of these responses. In vivo studies support a pathogenic role for caveolae in the progression of diabetic nephropathy. Targeting caveolin-1/caveolae would enable inhibition of multiple profibrotic pathways, representing a novel and potentially potent therapeutic option for diabetic nephropathy.
Authors: Yuzuru Ohshiro; Ronald C Ma; Yutaka Yasuda; Junko Hiraoka-Yamamoto; Allen C Clermont; Keiji Isshiki; Kunimasa Yagi; Emi Arikawa; Timothy S Kern; George L King Journal: Diabetes Date: 2006-11 Impact factor: 9.461
Authors: Alan Perlman; Loredo M Lawsin; Padmaja Kolachana; Motoyasu Saji; Jack Moore; Mathew D Ringel Journal: Ann Clin Lab Sci Date: 2004 Impact factor: 1.256
Authors: Elena Tourkina; Mathieu Richard; Pal Gööz; Michael Bonner; Jaspreet Pannu; Russell Harley; Pascal N Bernatchez; William C Sessa; Richard M Silver; Stanley Hoffman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2008-01-18 Impact factor: 5.464
Authors: Charles W Heilig; Dilip K Deb; Afu Abdul; Hasan Riaz; Leighton R James; Jamal Salameh; N Stanley Nahman Journal: Am J Nephrol Date: 2013-06-26 Impact factor: 3.754
Authors: Jacob W Myerson; Bruce Braender; Olivia Mcpherson; Patrick M Glassman; Raisa Y Kiseleva; Vladimir V Shuvaev; Oscar Marcos-Contreras; Martha E Grady; Hyun-Su Lee; Colin F Greineder; Radu V Stan; Russell J Composto; David M Eckmann; Vladimir R Muzykantov Journal: Adv Mater Date: 2018-06-28 Impact factor: 30.849
Authors: Vladimir V Shuvaev; Makan Khoshnejad; Katherine W Pulsipher; Raisa Yu Kiseleva; Evguenia Arguiri; Jasmina C Cheung-Lau; Kathleen M LeFort; Melpo Christofidou-Solomidou; Radu V Stan; Ivan J Dmochowski; Vladimir R Muzykantov Journal: Biomaterials Date: 2018-09-12 Impact factor: 12.479
Authors: Jacob S Brenner; Raisa Yu Kiseleva; Patrick M Glassman; Hamideh Parhiz; Colin F Greineder; Elizabeth D Hood; Vladimir V Shuvaev; Vladimir R Muzykantov Journal: Pulm Circ Date: 2017-12-20 Impact factor: 3.017
Authors: Neel Mehta; Dan Zhang; Renzhong Li; Tony Wang; Agata Gava; Pavithra Parthasarathy; Bo Gao; Joan C Krepinsky Journal: Cell Commun Signal Date: 2019-04-17 Impact factor: 5.712
Authors: A Mitrofanova; S K Mallela; G M Ducasa; T H Yoo; E Rosenfeld-Gur; I D Zelnik; J Molina; J Varona Santos; M Ge; A Sloan; J J Kim; C Pedigo; J Bryn; I Volosenco; C Faul; Y H Zeidan; C Garcia Hernandez; A J Mendez; I Leibiger; G W Burke; A H Futerman; L Barisoni; Y Ishimoto; R Inagi; S Merscher; A Fornoni Journal: Nat Commun Date: 2019-06-19 Impact factor: 14.919